title: Protection against aspirin-induced human gastric mucosal injury by bosentan, a new endothelin-1 receptor antagonist.
abstract: BACKGROUND
  Gastric ulceration induced by aspirin and by non-steroidal anti-inflammatory drugs (NSAIDs) is a major clinical problem. The mechanism of injury is unclear. There is evidence that NSAID-induced injury may cause endothelin activation. Endothelin-induced vasoconstriction has been shown to be capable of causing gastric ulceration.
  
  
  OBJECTIVE
  To investigate whether acute gastroduodenal injury induced in humans by aspirin can be prevented by the endothelin-1 antagonist, bosentan.
  
  
  METHODS
  Eighteen healthy volunteers each received 5 x 900 mg aspirin every 12 h on three separate occasions (with either placebo, bosentan 700 mg or misoprostol 400 mg). Treatment order was randomized by Latin square design. Subjects were endoscoped and erosions counted before and 90 min after the first and last dose of aspirin. Plasma concentrations of bosentan were measured up to 5 h post-dose.
  
  
  RESULTS
  There was a significant reduction in the mean number of erosions in the aspirin plus bosentan and aspirin plus misoprostol groups after the first dose of aspirin, compared with controls (aspirin plus placebo) (P<0.05). This was not sustained after the fifth dose of aspirin in the aspirin plus placebo and aspirin plus bosentan groups, but was still present in the aspirin plus misoprostol group. The mean plasma concentration of bosentan measured 3.5 h post-dose fell from 4510 (95% CI: 2791-6230) ng/mL after the 1st dose to 2508 (95% CI: 1733-3283) ng/mL after the 5th dose (P = 0.02).
  
  
  CONCLUSIONS
  Endothelin receptor antagonism by bosentan can protect the gastric mucosa against aspirin damage. After five doses, bosentan levels fell, possibly because of enzyme induction, and protection was no longer evident. Further investigation is needed to assess whether higher doses would be effective.
authors.affiliation: Division of Gastroenterology, University Hospital, Nottingham, UK.
authors.forename: A E
authors.initials: AE
authors.lastname: Duggan
authors.forename: W
authors.initials: W
authors.lastname: Stack
authors.forename: M
authors.initials: M
authors.lastname: Hull
authors.forename: B
authors.initials: B
authors.lastname: Filipowicz
authors.forename: A
authors.initials: A
authors.lastname: Knifton
authors.forename: R
authors.initials: R
authors.lastname: Crome
authors.forename: C
authors.initials: C
authors.lastname: Weber
authors.forename: A
authors.initials: A
authors.lastname: Bishop
authors.forename: J
authors.initials: J
authors.lastname: Polak
authors.forename: C J
authors.initials: CJ
authors.lastname: Hawkey
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001241:Aspirin / Q000009:adverse effects*; D000077300:Bosentan; D018592:Cross-Over Studies; D015232:Dinoprostone / Q000032:analysis; D004311:Double-Blind Method; D065128:Endothelin Receptor Antagonists; D005753:Gastric Mucosa / Q000737:chemistry / Q000187:drug effects*; D006801:Humans; D008297:Male; D016595:Misoprostol / Q000494:pharmacology; D044022:Receptor, Endothelin A; D013449:Sulfonamides / Q000097:blood / Q000494:pharmacology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D065128:Endothelin Receptor Antagonists; D044022:Receptor, Endothelin A; D013449:Sulfonamides; D016595:Misoprostol; D015232:Dinoprostone; D000077300:Bosentan; D001241:Aspirin